Piramal Pharma Share Price Target 2025, 2026, 2027 to 2030

Do you want to know the Piramal Pharma share price target for the year 2025? Here, you will get a detailed analysis of the company’s financial performance, historical data, and price target for the year 2025, 2026, 2027, 2028, 2029, and 2030 provided by the market experts and analysts.

About Piramal Pharma Limited

Piramal Pharma is an Indian company that makes medicines to help people feel better. It started working as a separate company in 2020 and is based in Mumbai. The company makes different kinds of medicine, like those used in hospitals and some you can buy at a shop without a doctor’s note. Piramal also helps other companies by making and testing their medicines. It sells its products in many countries. The goal of Piramal Pharma is to make good-quality medicine that helps people stay healthy.

Piramal Pharma Fundamentals

• Market Cap: ₹27,628.42 Cr.
• P/E Ratio: 39.96
• Book Value: ₹55.62
• Dividend Yield: 0.07 %
• ROE: 9.83 %
• ROCE: 12.40%
• 52-Week High: ₹307.85
• 52-Week Low: ₹145.55

Piramal Pharma Shareholding Pattern

• Promoter: 34.95%
• FII: 31.49%
• DII: 2.05%
• Public: 12.73%
• Others: 18.78%

Piramal Pharma Share Price Historical Data

Piramal Pharma Share Price Target 2025 to 2030

Year Wise Analysis

Piramal Pharma is a growing name in the healthcare industry, and its future looks promising. According to market expectations, the share price could reach ₹245 by 2025. If the company continues to grow and launch new products, the price may rise to ₹390 in 2026.

Piramal Pharma works in areas like drug manufacturing, healthcare solutions, and partnerships with global companies. These efforts may help the share price reach ₹530 by 2027. In 2028, the target is expected to climb to ₹720, showing strong investor confidence.

If the company keeps up its progress and improves its profits, the share may touch ₹890 in 2029. Looking ahead, the price might even rise to ₹1180 by 2030, reflecting long term growth. The company focus on research, innovation, and global partnerships could be key reasons behind this steady rise.

For investors thinking long term, Piramal Pharma might be a good option to watch. It is important to remember that stock prices can go up and down, and nothing is guaranteed. Doing your own research and understanding the risks is always a smart step before investing. Piramal Pharma’s journey in the pharma world is still growing, with much more to come.

Also Read: TCS Share Price Target 2025, 2026, 2027 to 2030

Piramal Pharma Financials

In the financials section of Piramal Pharma Ltd, we will discuss its income statement and balance sheet, so you can decide whether this stock is good for you or not for trade.

Piramal Pharma Income Statement

This company earned ₹2,754 crore, which is a little more than last year. It spent ₹1,481 crore to run the business — and that cost was much higher than before. Still, it made a profit of ₹154 crore, which is a good improvement. Each share gave ₹1.16 to its owner. The company is earning more and saving more, though its costs are growing fast too. It should keep an eye on spending.

Piramal Pharma Balance Sheet

The company owns things worth ₹15,678 crore in total. Out of that, ₹521 crore is in cash and short-term savings — a small increase. It has to pay ₹7,552 crore to others. After paying that, ₹8,125 crore is left, which belongs to the owners. The company has around 132 crore shares. It’s in a good financial position and is growing steadily.

Piramal Pharma Peer Companies

The peer companies of Piramal Pharma Limited which are in tough competition are Sun Pharmaceutical Industries, Cipla, Dr. Reddy’s Laboratories, Lupin, Aurobindo Pharma, Zydus Lifesciences, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon, Jubilant Pharmova, Laurus Labs, Divi’s Laboratories.

F&Q

Rishi Gupta